Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United States based President operating in the Health Diagnostics space. If you think a President is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Thomas Joyce
President & CEO of Danaher
Thomas Joyce is President and Chief Executive Officer of Danaher Corporation, a position he assumed in September 2014. Thomas is responsible for the company’s strategic vision and leads the development and growth of Danaher’s global science and technology portfolio. Thomas has more than 20 years of Danaher leadership experience. Prior to his appointment as President and Chief Executive Officer, he served as Executive Vice President of Danaher Corporation, responsible for Danaher’s Water Quality platform and Life Sciences & Diagnostics segment. In this role, Thomas increased Danaher’s Water Quality revenue by over $1.5 billion and led the company’s major acquisitions of Beckman Coulter and AB SCIEX. Throughout his tenure, Thomas has also played a key role in developing and evolving the Danaher Business System, Danaher’s common operating philosophy. Thomas began his Danaher career in 1989 as a Project Manager in the Danaher Tool Group, and later transitioned into a manufacturing role. In 1995, Thomas became President of Delta Consolidated Industries. Following this assignment, he became President of Hach Company, the world leader in analytical instrumentation for drinking water and wastewater applications in 2001. In 2002, Thomas became a Group Executive and Corporate Officer with Danaher Corporation, which led to his transition to Executive Vice President in 2006. Prior to joining Danaher, Thomas worked as a management consultant at Anderson Consulting, where he worked with a large number of manufacturing businesses to implement lean tools and optimize transactional processes. Thomas was born and raised on the north shore of Chicago and earned his bachelor’s degree in Economics from the College of the Holy Cross in 1982. He and his wife, Claire, live in Washington, D.C. and have four children.
Follow Thomas Joyce:
About Danaher: Danaher is a global science and technology innovator committed to helping their customers solve complex challenges and improve quality.
_______
William H. King, IV
Senior Vice President, Strategic Development of Danaher
Mr. King is the Senior Vice President, Strategic Development for Danaher Corporation. Mr. King and his team drive market development, deal sourcing and commercial diligence at Danaher, thus co-owning the M&A process at Danaher with Mr. Daniel Raskas and the Corporate Development team. In addition, he and his team hold responsibility for the strategic planning process, tools and training. Mr. King joined Danaher in 1998 and has held positions as Managing Director of the Special Purpose Systems Motion Control Group, as well as Vice President of Sales and Marketing for the Motion Control Group. Prior to joining Danaher, he held positions of increasing responsibility in live production and logistics for Perdue, Inc. Mr. King has an MBA from Harvard Business School and a BS in Economics from University of Maryland.
Follow William H. King, IV:
About Danaher: Danaher is a global science and technology innovator committed to helping their customers solve complex challenges and improve quality.
Ronald Hutton
Vice President, Treasurer of Bio-Rad Laboratories
Follow Ronald Hutton:
About Bio-Rad Laboratories: Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of
James Stark
Vice President, Corporate Controller of Bio-Rad Laboratories
Follow James Stark:
About Bio-Rad Laboratories: Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of
Mike Crowley
Executive Vice President, Global Commercial Operations of Bio-Rad Laboratories
Follow Mike Crowley:
About Bio-Rad Laboratories: Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of
Timothy Ernst
Executive Vice President, General Counsel & Secretary of Bio-Rad Laboratories
Follow Timothy Ernst:
About Bio-Rad Laboratories: Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of
Junfeng Luo
Co-Founder & Vice President, R&D – NuProbe, China of NuProbe
Junfeng Luo is a Co-Founder and Vice President of R&D at NuProbe, China.
Follow Junfeng Luo:
About NuProbe: An early stage molecular diagnostics company.
Deepak Nath
President, Laboratory Diagnostics of Siemens Healthineers
Follow Deepak Nath:
About Siemens Healthineers: Siemens Healthineers is a healthcare technology company that provides diagnostic and therapeutic products and services.
Ron Pellegrini
Vice President & Head of Field Service LD/POC of Siemens Healthineers
Ron Pellegrini’s career with Siemens Healthcare spans over 20 years. It began as a licensed Medical Technologist specializing in Chemistry with the U.S. Air Force and at hospitals in Dallas / Fort Worth area. His experience led him to an engineering position with Ciba-Corning Diagnostics. He has held the position of Regional Service Manager and Technical Sales Manager for Chiron & Bayer Healthcare. He held the role of National Technical Sales Director at Siemens and was a Zone Vice President in the Midwest & Western Zones for both the In Vivo and In Vitro businesses prior to taking on his recent role as Vice President, Head of Field Service for LD/POC. Ron was awarded Rookie of the Year, Regional Manager & Director of the year, a three time President’s Club award winner and VP of the Year and a four time APEX winner while in his Service and Technical Sales Leadership positions. He is member of the American Medical Technologists (AMT), a mentor with the American Corporate Partners (ACP) for US Military Members, and is very active as a volunteer within his church community. Ron has been married for the past 29 years with four beautiful children. He enjoys traveling, golf and the watching the Dallas Cowboys. He holds Bachelors degree in Medical Technology from Midwestern State University in Wichita Falls, TX and has a Masters degree in Business.
Follow Ron Pellegrini:
About Siemens Healthineers: Siemens Healthineers is a healthcare technology company that provides diagnostic and therapeutic products and services.
Maynd Jolly
Vice President Strategic Corporate Accounts of Siemens Healthineers
Follow Maynd Jolly:
About Siemens Healthineers: Siemens Healthineers is a healthcare technology company that provides diagnostic and therapeutic products and services.
Sebastian Kronmueller
Vice President, Head of Strategy & Business Development – Laboratory Diagnostics of Siemens Healthineers
Sebastian Kronmueller incubates startup businesses within Healthineers with a focus on novel molecular applications. His current incubation businesses include the Siemens Healthcare Laboratory in Berkeley, California and NEO New Oncology in Cologne, Germany. Previously he led the execution of strategic initiatives as Head of Special Projects for Siemens Healthineers, playing an instrumental role in shaping the strategy of Siemens Healthineers in preparation for the IPO planned in 2018. Before this role he led a project management team for companion diagnostics and software development and was responsible for the carve-out and divestment of the Healthineers Microbiology business. He began his career as strategy consultant with Siemens Management Consulting. Sebastian holds a graduate degree in physics from Ludwig-Maximilians-University in Munich, Germany and a graduate certificate in Management Science and Engineering from Stanford University in Palo Alto, California.
Follow Sebastian Kronmueller:
About Siemens Healthineers: Siemens Healthineers is a healthcare technology company that provides diagnostic and therapeutic products and services.
Erik Holmlin
President, CEO of Bionano Genomics
Erik Holmlin has two decades of experience in the life science and health care industries. His expertise spans technology development and commercialization, global marketing, commercial operations, venture financing, mergers & acquisitions and intellectual property. Recently, he served as president and CEO of GenVault Corporation, a life science company bring innovative solutions to biosample management. He merged GenVault with IntegenX, Inc. in January of 2011. He also served as an entrepreneur in residence (EIR) at Domain Associates, LLC, a leading dedicated life science venture-capital firm. Prior to these roles, Erik was chief commercial officer at Exiqon A/S, where he was responsible for global sales, marketing, and clinical affairs for two businesses: Oncology Services in a CLIA lab and Consumables Business in Life Sciences Research. In 2001 Mr. Holmlin led the formation of GeneOhm Sciences, Inc., for which, over a span of 5 years, he was director of chemistry, senior technology director, vice president of technology and business development, and vice president of marketing.
Follow Erik Holmlin:
About Bionano Genomics: BioNano Genomics develops nanoscale imaging and analytic platforms designed to analyze DNA and other genome-related peptides and proteins.
Richard Compton
Vice President of Commercial Operations of Oxford Nanopore Technologies
Rich joined Oxford Nanopore from Illumina where he played a key role as Vice President and General Manager of the EMEA Region. Metrichor was founded to provide real-time, integrated analysis solutions based on nanopore sensing technology to the Clinical and Applied markets. Prior to Illumina, Rich gained twelve years of experience helping commercial & research customers successfully integrate and deploy enterprise scale software solutions in both research and quality/regulated environments as Vice President & General Manager EMEA of Dassault Systèmes Biovia unit.
Follow Richard Compton:
About Oxford Nanopore Technologies: Oxford Nanopore Technologies develops nanopore-based electronic systems for analyzing single molecules, including DNA, RNA, and proteins.
Hamid Rategh
Vice President Engineering of Genapsys
Hamid is VP Engineering at GenapSys, joining back in 2012. Hamid has had a successful career developing a wide range of products, from RFICs to adaptive equalizers for optical communication and Mixed-Signal Memory interface products. Prior to joining GenapSys, Hamid was Senior Director of Engineering at Inphi, who acquired his team and product from Scintera Networks. Hamid also cofounded and served as VP of Engineering of Tavanza which was later acquired by Celeritek in 2002 and subsequently by Anadigics in 2003. Hamid holds a PhD in Electrical Engineering from Stanford University, and an MS in Biomedical Engineering from Case Western Reserve University. He earned his BS in Electrical Engineering from Sharif University of Technology.
Follow Hamid Rategh:
About Genapsys: Transform the human condition by building a scalable, affordable genomic sequencing ecosystem that will support research and diagnostics
Johannes Fruehauf
Founder, President & Executive Director of LabCentral
Johannes Fruehauf is the Founder & CEO LabCentral/Biolabs.He is responsible for all aspects of LabCentral’s operation. Johannes is a physician and successful biotech entrepreneur. Prior to LabCentral, he founded Cambridge Biolabs, a contract research facility serving startup and virtual companies in Kendall Square. He is also a co-founder of ViThera Pharmaceuticals, Deltix and Cequent Pharmaceuticals, and an advisor or board member to numerous life sciences companies and non-profits. Johannes earned his medical degree at the University of Frankfurt and his PhD at the University of Heidelberg (Germany).
Follow Johannes Fruehauf:
About Arkuda Therapeutics, BioLabs, Cequent Pharmaceuticals, Deltix, LabCentral, Mission BioCapital: LabCentral developing novel cancer treatments: Conkwest, Inc, headquartered in DelMar, California, is opening its research laboratory at
Greg Gosch
Co-Founder, President, & CEO of ChromaCode
Greg has over 20 years of management experience in the molecular diagnostics and nucleic acids research fields. He spent 9 years at Luminex, when the company grew revenues from $30 million to over $200 million. He held multiple roles including VP of Sales and Marketing, where he was responsible for global commercial operations, and VP/GM of Biosciences, where was responsible for developing novel instrument and assay products for gene expression, microRNA, newborn screening and Alzheimer’s disease. Prior to Luminex, Greg served in various commercial leadership roles at Nanogen, Chiron Diagnostics and Bio-Rad. He has a bachelors degree in molecular, cellular and developmental biology from the University of Colorado and dual masters degrees in business and healthcare administration from the University of Minnesota.
Follow Greg Gosch:
About ChromaCode: ChromaCode is a molecular diagnostics company focusing on bioinformatics.
Amit Vohra
Co-Founder, President & CEO of Promaxo
Promaxo is led by Dr. Amit Vohra who is a serial entrepreneur, business strategist and advisor to several healthcare and technology startups. Amit is a Partner in Advanced Biopharma Consulting, a management consultancy offering strategic business development and commercialization services in the life sciences space. He also serves as an advisor to Cricking, MedDx and HealthyX and a strategy consultant to Precision Biopsy and Weinberg Medical Physics. Prior to Promaxo, Amit was the CEO/President of Convergent Life Sciences wherein he took a MRI-US fusion product, for targeted laser ablation of soft tissue cancer, through FDA clearance within 18 months of Company formation. Previously, as VP of Strategy and Operations at Eigen, he led the development and successful commercialization of two class II medical devices in the prostate biopsy space. In 2009, Amit co-founded Navya Biomedical Technologies, a biotechnology company using proprietary polyhydroxy fullerenes (PHF) for non-invasive imaging and destruction of solid tumors. Amit has a Doctorate in Mechanical Engineering from University of Florida, and an Executive MBA (Fuqua Scholar) from Duke University’s Fuqua School of Business.
Follow Amit Vohra:
About 8chili, Neuro42, Promaxo, TriOcula Technologies: Promaxo is commercializing customer-centric MRI systems and robotic guidance tools for live diagnosis and treatment in a physician’s office.
Kathryn Zavala
Vice President, Business Development & Operations of MedTech Innovator
Follow Kathryn Zavala:
About MedTech Innovator: MedTech Innovator is the largest lifescience accelerator in the world for medical device, digital health, and diagnostic companies
Jeffrey Mathers
Vice President, Commercial Technology, Software Engineering, R&D Platforms, and Architecture of Johnson & Johnson
Follow Jeffrey Mathers:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Vaibhav Narayan
Vice President, Digital Health Innovation of Johnson & Johnson
Follow Vaibhav Narayan:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Ravi Parameswar
Vice President, Head of Global Strategic Insights & Analytics of Johnson & Johnson
Follow Ravi Parameswar:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Nicholas Pachuda
Worldwide Vice President,Orthopedic Innovation,External Innovation & Enabling technologies of Johnson & Johnson
Follow Nicholas Pachuda:
About Johnson & Johnson, Peptilogics: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Amy Foley
Vice President, Product Innovation & Delivery of Johnson & Johnson
As Vice President of Product Innovation & Delivery, Amy Foley leads the Johnson & Johnson portfolio of health and wellness capabilities, including new product and service innovation, creation, implementation, operations, customer service and compliance and quality.
Follow Amy Foley:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Jane Adams
Vice President, Federal Government Affairs of Johnson & Johnson
Follow Jane Adams:
About Johnson & Johnson, Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Hartmuth Kolb
Vice President, Neuroscience Biomarkers and Janssen R&D Global Imaging of Johnson & Johnson
Follow Hartmuth Kolb:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Cat Oyler
Vice President, Global Public Health, Tuberculosis of Johnson & Johnson
Cat Oyler serves as vice-president of global public health (GPH) at Johnson & Johnson (J&J), leading the tuberculosis (TB) focus area strategy team (FAST), and as a member of the GPH executive leadership team. In this role, Cat leads the enterprise TB FAST to deliver on J&J’s aspiration to create a world without tuberculosis through ending mortality from multidrug-resistant tuberculosis. Cat previously served as global head of strategy and operations for J&J Innovation (JJI). She had responsibility for aligning the World Without Disease Accelerator, Lung Cancer Initiative, and JJI organizations to accelerate innovation in order to prevent, intercept and cure disease. Before this, Cat held the role of vice-president of strategy and external innovation for Janssen Research and Development, the global R&D arm of Janssen Pharmaceutical Companies of Johnson & Johnson. Here, she directed the development of the company’s long-term ‘A World Without Disease’ strategy, focusing on transforming human health. Additionally, Cat is an Aspen Institute First Mover Fellow and serves as executive sponsor for the university workstream for Women in Science, Technology, Engineering, Math, Manufacturing, and Design (WiSTEM2D).
Follow Cat Oyler:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Samantha Steinwinder
Vice President of Corporate Marketing of Accolade
Samantha Steinwinder is the Vice President of Corporate Marketing at Accolade, Inc. She oversees Corporate Marketing for the healthcare technology innovator that is reinventing the way individuals and organizations experience healthcare. Ms. Steinwinder is a former Managing Partner at The Concept Agency and Vice President of Weber Shandwick. Samantha received a bachelor of arts in Communication at Menlo College.
Follow Samantha Steinwinder:
About Accolade: Accolade features personalized health and benefits solutions that help to improve experience, outcomes, and healthcare cost for employers.
Tara O’Meara
Vice President, Clinical Development Operations of Bluebird Bio
Tara O’Meara is the Vice President of Clinical Development Operations at bluebird bio. Tara oversees a team responsible for the execution and analysis of bluebird bio’s lentiviral vector based gene therapy development programs. Currently bluebird bio has 4 active programs using ex vivo gene therapy for: cerebral adrenoleukodystrophy, transfusion dependent thalassemia, sickle cell disease and multiple myeloma. bluebird’s objective is to develop and bring to market the most advanced products based on the transformative potential of gene therapy as a one-time treatment option for patients with severe genetic and rare diseases and cancer. Prior to joining bluebird, Tara ran multiple clinical trials in 2 other rare diseases, LAL Deficiency and Pompe disease. Tara served as the clinical project manager for the clinical trials that were used as the basis for the regulatory submissions that led to the approval of Myozyme™ in the United States, Europe, and more than 40 additional countries worldwide. Tara has also been responsible for everything from small Phase II trials to very large, global Phase III trials in multiple therapeutic areas, including rare inherited diseases. Tara holds a BS in biology and a minor in women’s studies from Tufts University.
Follow Tara O’Meara:
About Bluebird Bio: Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
Kevin Mosher
President & CEO of ClearChoice Holdings
Kevin Mosher is an executive with more than 20 years experience in the dental and medical technology industries, and currently serves as President and CEO of ClearChoice Holdings, a nationwide network of dental implant centers that specialize in the treatment of the fully edentulous. Following a five-year stint as a logistics officer in the US Navy, Kevin began his medical career in sales and marketing with Baxter Healthcare, Johnson and Johnson (Ethicon and Advanced Sterilization Products), and Masimo Corporation. As President of startup medical device manufacturer Masimo Corp, Kevin led the commercial activities of an organization that grew from $12 – $70M during his three-year tenure. Following Masimo, he served as President of dental implant manufacturer Nobel Biocare’s North American division where divisional revenues more than doubled from $140M to $315M over a six-year period. Prior to his current position at ClearChoice, Kevin served as President and CEO of medical device startup DFINE, Inc, a company focused on the minimally invasive treatment of diseases of the spine. He holds a B.S. in Applied Engineering Sciences from the U.S. Naval Academy.
Follow Kevin Mosher:
About ClearChoice Holdings: ClearChoice is a network of dental treatment centers that provide innovative and quality dental implant care across the United States.
Robert Ford
President & Chief Executive Officer of Abbott
Follow Robert Ford:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Michael Warmuth
Executive Vice President of Abbott
Michael Warmuth is Executive Vice President, Established Pharmaceuticals, focusing on expanding the global market for Abbott’s portfolio of branded generic pharmaceuticals. He was appointed to his current role in November 2012. Most recently, Mr. Warmuth served as Senior Vice President, Established Pharmaceuticals, which previously operated as part of Abbott’s global pharmaceutical business. Mr. Warmuth joined Abbott in 1986 as part of Abbott’s manufacturing professional development program. He served in a variety of management roles including Senior Vice President, Diagnostics, heading Abbott’s global core laboratory Diagnostics business; Vice President and General Manager, Hematology, in Abbott’s Diagnostics business; Vice President, Global Engineering Services; Divisional Vice President of Pharmaceutical Operations; and Divisional Vice President of Corporate Quality Operations. He earned a bachelor’s degree in business administration from the University of Wisconsin-Whitewater and a master’s degree in business administration from Northwestern University.
Follow Michael Warmuth:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Heather Mason
Executive Vice President, Nutritional Products of Abbott
Heather Mason is Executive Vice President, Nutritional Products. She was appointed to her current role in May 2015. Previously, she served as Executive Vice President, Global Commercial Operations, Abbott Nutrition. Ms. Mason joined Abbott in 1990. She held a number of positions in Abbott’s U.S. pharmaceutical business, including oversight of Abbott’s specialty pharmaceuticals, its diabetes/metabolics and oncology franchises, and managed health care. Ms. Mason also served as Vice President, International Marketing, and Vice President, Latin American Operations, in Abbott’s international pharmaceutical business. Immediately prior to assuming her role in Abbott’s Nutrition business in 2014, Ms. Mason served as Senior Vice President, Abbott Diabetes Care. Prior to joining Abbott, Ms. Mason worked for Quaker Oats and FMC Corporation. She is an advisory board member of the Healthcare Businesswomen’s Association. She earned a bachelor’s degree in engineering from the University of Michigan and a master’s degree in business administration from the University of Chicago.
Follow Heather Mason:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Corlis Murray
Senior Vice President, Quality Assurance, Regulatory & Engineering Services of Abbott
Corlis Murray is Senior Vice President, Quality Assurance, Regulatory and Engineering Services. She was appointed to her current position in February 2012. Previously, she served as Vice President, Global Engineering Services. Ms. Murray joined Abbott in 1989. Since then, she has held a number of management positions in quality, operations and engineering in Abbott’s Diagnostics and Nutrition businesses. In Abbott Nutrition, she served as Divisional Vice President, Quality Assurance; Divisional Vice President, Manufacturing; and Divisional Vice President, Operations Services. Prior to joining Abbott, Ms. Murray worked at Recognition Equipment and Xerox Corporation. She is a board member of The Clara Abbott Foundation. She earned a bachelor’s degree in mechanical engineering from Southern University in Baton Rouge, Louisiana.
Follow Corlis Murray:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
John Capek
Executive Vice President of Abbott
John Capek, Ph.D., is Executive Vice President, Ventures. Dr. Capek was appointed to his current position in June 2015. In this role, he leads Abbott’s venture investment organization as well as new ventures, including Abbott Electrophysiology. Previously, he had served as Executive Vice President, Medical Devices, and Senior Vice President, Abbott Vascular, heading up Abbott’s global vascular business. Before joining Abbott, Dr. Capek served in various management roles at Guidant Corporation, including president, Guidant Vascular Intervention and vice president and general manager of Bioabsorbable Vascular Solutions. He also served as vice president and general manager of Guidant Germany and vice president, marketing, Guidant Cardiac Rhythm Management Group. Before joining Guidant, Dr. Capek was manager of New Product Technology at Eli Lilly & Company. He has a bachelor’s degree in biomedical engineering, a master’s degree in biomedical engineering, a master’s degree in electrical engineering, a Ph.D. in biomedical engineering and a master’s degree in business administration from Rensselaer Polytechnic Institute.
Follow John Capek:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Roger Bird
Senior Vice President, U.S. Nutrition of Abbott
Roger Bird is Abbott’s Senior Vice President, U.S. Nutrition. He was appointed to this role in February 2015. Prior to assuming his current position, Roger served as Divisional Vice President, General Manager for our Nutrition business in China and Hong Kong. Roger came to Abbott in 1983 from the Dial Soap Company, where he worked as a sales representative. He joined Abbott as Trade Sales Manager in our Nutrition organization, and has served in this business throughout his Abbott career, contributing to our company’s success in both the U.S. and Asia. While leading Abbott’s nutrition business in China, he oversaw the successful launch of Similac Eleva and Similac Qinti, two infant formula products that significantly strengthened Abbott’s presence in this important market. Throughout his career, Roger has taken real pride in contributing to the Abbott Nutrition mission of providing high-quality products that help improve the lives of people of all ages, all around the world. In addition to his responsibilities with Abbott. Roger serves on the Board of the Grocery Manufacturers Association. Roger earned his bachelor’s degree in Business Management from Weber State University in Ogden, Utah.
Follow Roger Bird:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Steve Fussell
Executive Vice President, Human Resources of Abbott
Steve Fussell is Executive Vice President, Human Resources. He was appointed in February 2013. Mr. Fussell joined Abbott in 1996, as Divisional Vice President, Compensation and Benefits. He was promoted to Vice President, Compensation and Development in 1999, and to Senior Vice President, Human Resources in 2005. Prior to Abbott, he held human resources leadership positions at Nestlé and Shell. Mr. Fussell is Chairman of the Board and President of the Clara Abbott Foundation and a board member of the Abbott Fund. He is an author and speaker on a wide variety of subjects and has served as a guest lecturer at Cornell and other universities. In 2010, he was named to the HR Honor Roll by Human Resources Executive magazine. He earned a bachelor’s degree from Louisiana State University in Baton Rouge.
Follow Steve Fussell:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Jean-Yves Pavée
Senior Vice President of Abbott
Jean-Yves Pavée is Senior Vice President, Developed Markets for Abbott’s Established Products Division. He was appointed to his role in July 2013. Previously, he served as Divisional Vice President, EMEA East, and Division Vice President, Pharmaceuticals, Europe South. Mr. Pavee joined Abbott in 1992, after serving as European Sales Manager, France for Aguettant, S.A. Mister Pavée received his undergraduate degree from the Ecole Supérieure des Sciences Commerciales d’Angers, France; and his MBA from HEC Paris MBA, Jouy-en-Josas, France.
Follow Jean-Yves Pavée:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Brian Yoor
Senior Vice President Finance & Chief Financial Officer of Abbott
Brian Yoor is Senior Vice President Finance and Chief Financial Officer. He was appointed to his current position in June 2015. He previously served as Vice President, Investor Relations. Brian joined Abbott in August 1997, and held various financial management positions of increasing responsibility, including Controller positions in the pharmaceutical, nutrition, and diagnostic businesses, before being asked to lead Abbott’s Investor Relations effort in January 2013. Prior to joining Abbott, Brian was a certified public accountant with Arthur Andersen and held financial positions in the consumer industry with the Scotts Company and Newell Rubbermaid. “In Abbott Finance, we are the stewards that enable financial reliability and growth for Abbott, “ Says Brian. “ A strong, growing company is better able to help people around the world live their healthiest lives.” Brian serves on the board of the Clara Abbott Foundation. He is a member of NIRI, the National Investor Relations Institute. He earned his bachelor’s degree in accounting at the University of Toledo in Ohio.
Follow Brian Yoor:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Hubert L. Allen
Executive Vice President, General Counsel & Secretary of Abbott
Hubert L. Allen is Executive Vice President, General Counsel and Secretary. He was appointed to his current role in January 2013. Previously, he served as Divisional Vice President and Associate General Counsel, Established Pharmaceuticals. Mr. Allen joined Abbott in 2006 as Senior Counsel, supporting the Pharmaceutical Products Division. He has held various positions within the legal department, including Divisional Vice President and Associate General Counsel, Pharmaceutical Products Group; Section Head, Nutrition Legal Operations; and Division Counsel, supporting the Pharmaceutical Products Division. Prior to joining Abbott, Mr. Allen was Assistant General Counsel for McKesson Corporation. He graduated with a bachelor’s degree from the College of Social Studies at Wesleyan University in Middletown, Connecticut; a master’s degree in Politics from Princeton University in Princeton, New Jersey, and a juris doctorate from Yale Law School in New Haven, Connecticut.
Follow Hubert L. Allen:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Thomas Frinzi
Senior Vice President of Abbott
Thomas Frinzi is Senior Vice President of Abbott’s vision business, which includes a broad ophthalmology portfolio across the areas of cataracts, refractive surgery (LASIK) and eye health products. He was appointed to his position in January 2016. Prior to joining Abbott, Mr. Frinzi held a number of leadership positions in ophthalmology and medical device companies. Most recently, he served as President and CEO of WaveTec Vision, a developer of surgical systems for eye surgery. He also held senior positions in commercial operations, business development, and sales and marketing at Bausch & Lomb Surgical, Refractec and Johnson & Johnson. In recognition of his leadership, expertise and vision in the field, Mr. Frinzi was awarded the 2015 Ophthalmology Innovation Award by the Ophthalmology Innovation Summit. He earned a bachelor’s degree in political science from the University of Tampa.
Follow Thomas Frinzi:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Mark McKenna
Founder, President and CEO of Prometheus Biosciences
Mark McKenna currently works as President and Chief Executive Officer at Prometheus Biosciences. He previously worked at Bausch + Lomb as Senior Vice President and General Manager.
Follow Mark McKenna:
About Prometheus Biosciences: Prometheus Biosciences develops and commercializes pharmaceutical and diagnostic products to help physicians individualize patient care.
Steve Pham
Vice President of Clinical and Research Affairs of Eko Health
Steve Pham is a practicing emergency medicine physician, the head of medical and research affairs at Eko, and a new father. His passion is translating between digital and clinical insights.
Follow Steve Pham:
About Eko Health: Eko develops AI-powered digital tools to detect and monitor heart and lung disease
Parker Cassidy
Vice-President of Strategy and Business Development of Farcast
Parker leads worldwide commercial operations for Mitra Biotech, a pioneer in novel technologies to better predict personalized therapy response in oncology. Mitra’s proprietary CANScriptTM assay tests how a patient’s tumor responds to numerous therapy combinations while retaining the critical components of the tumor microenvironment, including the immune compartment and heterogeneity. Mitra has demonstrated an extremely high correlation between its in-vitro predictions and what happens in-vivo in the clinic across different tumor types and drug classes. Importantly, the company has also demonstrated that immune checkpoint inhibitors can be successfully tested on the platform. Parker works with clinicians to demonstrate CANScriptTM clinical utility, and with biopharma clients to use the system as models for patient response – speeding development of new drugs. For over 15 years, Parker has been developing and launching novel diagnostic and drug discovery products and services with companies including BD and Upstate Biotechnology (now EMD Millipore).
Follow Parker Cassidy:
About Farcast: Farcast develops a diagnostic platform that delivers powerful predictions for personalized cancer treatment selection and drug development.
Pat Patnode
President of Licensing of GE Ventures
Patrick Patnode is the President of Licensing at GE Ventures.
Follow Pat Patnode:
About GE Ventures: GE Ventures combines capital, expertise, infrastructure, and the GE global network to help accelerate the growth of businesses.
James Hinrichs
Executive Vice President and Chief Financial Officer of Alere
James (“Jim”) Hinrichs joined Alere in April 2015 as Executive Vice President and Chief Financial Officer, with global responsibility for Finance, Accounting, Procurement, IT and Shared Services. Prior to his appointment as CFO of Alere, Jim Hinrichs was CFO at CareFusion Corp., a global medical technology corporation, since 2010. He held this position through the completion of Becton Dickinson’s acquisition of CareFusion in March 2015. Prior to this role, Hinrichs served as SVP of Global Customer Support and, before that, Corporate Controller of CareFusion. Previously, he was Executive Vice president and Controller of Cardinal Health, CFO of Cardinal Health’s Clinical and Medical Products segment and CFO of Cardinal Health’s Healthcare Supply Chain Services segment.. He joined Cardinal Health in February 2004, following 12 years of finance and marketing roles at Merck & Co. and two years as the CFO of SangStat Medical Corporation.
Follow James Hinrichs:
About Alere: Alere provides diagnostics and health management solutions for infectious, heart and cancer-related diseases and drug addicts.
Mark Gladwell
Senior Vice President, Global Operations of Alere
Mark Gladwell has served as Senior Vice President, Global Operations since January 2015. From January 2014 through January 2015, he held the role of Vice President, Operations for North America, Europe, Middle East and Africa. From September 2011 through December 2013, Mr. Gladwell served as Vice President of Operations for North America and as President and General Manager of one of Alere’s key manufacturing facilities in North America. From 2007 to 2010 Mr. Gladwell was Vice President, Quality and Technical Service for Alere. From 2005 to 2007, he served as a director covering multiple functions in the start-up of Alere Technology Limited where he focused on the development and manufacture of the Alere home BNP product. Prior to 2005 Mr. Gladwell held a variety of operations, quality and project leadership positions in North America and Europe for Alere, Johnson & Johnson, Agfa Gavert and DuPont. Mr. Gladwell has more than 18 years of experience in manufacturing high-volume, high-technology in-vitro diagnostics and medical devices.
Follow Mark Gladwell:
About Alere: Alere provides diagnostics and health management solutions for infectious, heart and cancer-related diseases and drug addicts.
Giulio Ruffini
President, CSO and co-founder of Neuroelectrics
Dr. Giulio Ruffini is the CEO and CTO of Starlab and the president and CSO of Neuroelectrics. He obtained a BA in Mathematics & Physics from Berkeley and a PhD in theoretical physics from UC Davis/LANL in 1995. In 2000 he founded Starlab to transform science into high-impact technologies.
12 years later he founded Neuroelectrics, a company which combines high-precision multichannel stimulation technologies with advanced biophysical and neuro-computational models.
For the past 15 years, Giulio has been developing technology for and researching the use of non-invasive brain monitoring and brain stimulation techniques, with a focus on EEG and transcranial current stimulation. His paper on brain-to-brain telepathy communication was the top 10 most shared papers of 2014. He is currently leading or involved in several European programs such as Galvani ERC Synergy, STIPED or Neurotwin.
Follow Giulio Ruffini:
About Neuroelectrics: Neuroelectrics is a digital brain health company that diagnoses and treats brain disorders with personalized neuromodulation, and improves overall brain health.
Kurt Graves
President & CEO of Intarcia Therapeutics
Follow Kurt Graves:
About Intarcia Therapeutics: Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
David Franklin
Vice President, Commercial Operations of Intarcia Therapeutics
Mr. Franklin joined Intarcia in March 2006 as Vice President, Commercial Operations. Prior to joining Intarcia, Mr. Franklin was Senior Vice President, US Business Unit and Acting Senior Vice President, Global Marketing for Idenix Pharmaceuticals. As head of the US Business from March 2005 through March 2006, Mr. Franklin developed and executed plans for the commercialization of telbivudine, an antiviral for the treatment of chronic hepatitis B, and built the US Business Unit, an organization comprising approximately 40 Medical, Marketing and Sales personnel. From June 2003 until March 2005, Mr. Franklin served as Vice President, Commercial Operations, leading the Idenix Global Marketing group, directing brand development for telbivudine and for a phase II hepatitis C drug candidate and leading commercial efforts to form a global co-promotion and licensing alliance with Novartis AG. Prior to these responsibilities, Mr. Franklin held positions of increasing responsibility with Idenix as Executive Director, Marketing and Corporate Communications and Director, Marketing and played key roles in multiple private and public financing transactions and in business development and licensing transactions. Prior to joining Idenix in 1998, Mr. Franklin was Senior Product Manager, HIV Products for Bristol-Myers Squibb Co. with responsibility for Zerit and Videx, two antiviral therapies for the treatment of HIV infection. Prior to joining the HIV Products Division, Mr. Franklin held sales and sales administration positions within the Bristol-Myers Squibb Oncology Division from 1990 to 1995, responsible for sales force support, incentive compensation and alliance management. Mr. Franklin received a BA from Gettysburg College in 1988.
Follow David Franklin:
About Intarcia Therapeutics: Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
Ved Srivastava
Vice President, Chemistry of Intarcia Therapeutics
Follow Ved Srivastava:
About Intarcia Therapeutics, U.S. Pharmacopeial Convention (The United States Pharmacopeial Convention): Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
Andrew Young
Vice President & Chief Scientific Officer of Intarcia Therapeutics
Dr. Young joined Intarcia in September 2015 as Vice President and Chief Scientific Officer. Dr. Young is most recognized for his role in the discovery and development of peptide therapeutics for metabolic diseases. Prior to its acquisition by Intarcia, he co-founded and was CSO of Phoundry Pharmaceuticals Inc., a company dedicated to rendering peptides sufficiently potent for incorporation into innovative delivery systems such as Intarcia’s proprietary mini-pump technology. Dr. Young entered industry from academia 26 years ago as the founding physiologist at Amylin Pharmaceuticals, Inc. There he pioneered work that illuminated the role of the gut in blood glucose control. He co-led different phases of the development of pramlintide and exenatide, first-in-class medicines for the treatment of diabetes. His roles at Amylin included VP of Research and Senior Research Fellow. In 2008 he co-founded Satiogen Inc., a San Diego startup related to bile salt stimulation of gut hormone secretion, before joining GlaxoSmithKline in RTP, NC, as Head of Enteroendocrine Biology. At GSK he fostered the development of peptide therapeutics as well as non-absorbed medicines acting at gut targets. In 2015 he co-founded Phoundry Pharmaceuticals with five former GSK colleagues. Dr. Young received his medical degree as well as graduate science degrees from the University of Auckland School of Medicine, New Zealand, where he also taught physiology. He worked as a Fogarty Fellow for the NIH in Phoenix AZ, studying diabetes in Pima Indians. He worked as a Von Humboldt Fellow at the Max Planck Institute in Bad Nauheim, FRG, studying sensory neurophysiology. He has participated in the development of five drugs that were commercialized, written over 100 original papers and 37 book chapters or books, and is an inventor on 56 issued US patents.
Follow Andrew Young:
About Intarcia Therapeutics, Satiogen Pharmaceuticals: Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
Thomas Alessi
Vice President, Development and Manufacturing of Intarcia Therapeutics
Dr. Alessi joined Intarcia in December 1997 as Executive Director, Regulatory Affairs and Drug Development and was promoted to Vice President, Development in February 2002 with responsibility for the areas of product development, project management, chemistry and manufacturing. Prior to joining Intarcia, Dr. Alessi served as the Senior Director, Regulatory Affairs, Quality Assurance and Project Management at Ansan Pharmaceuticals where he was responsible for successful IND filings and for managing five drug development programs with oversight of vendors for preclinical and clinical studies and manufacturing clinical supplies. Before joining Ansan, Dr. Alessi was Director of Regulatory Affairs and Quality Assurance at Glycomed, Inc. where his duties included oversight and compliance of clinical manufacturing. His previous experience includes regulatory affairs and drug discovery experience in large pharmaceutical companies. Dr. Alessi was Senior Manager of Regulatory Affairs for Schering-Plough working in the Anti-infectives, Allergy Products and Chemisty, Manufacturing, & Controls groups. While at Schering-Plough, Dr. Alessi had regulatory responsibilities for approval and launch of interferon alfa-2b for hepatitis C as well as for hepatitis B. In his CMC role, he served on separate committees for process development and production of solid oral dosage forms, inhaled products, creams and semisolid products and sterile dosage forms, in addition to regulatory review of the CMC sections of Schering-Plough INDs and NDAs. Prior to joining Schering-Plough, Dr. Alessi invented and patented several new families of antidiabetic drugs while working as a Senior Scientist in the drug discovery group at Wyeth-Ayerst. Dr. Alessi earned a B.S. degree at Allegheny College and an M.S. and a Ph.D. in organic synthetic chemistry from the University of Rochester.
Follow Thomas Alessi:
About Intarcia Therapeutics: Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
Neal Meropol
Vice President, Head of Medical and Scientific Affairs of Flatiron Health
Neal J. Meropol is a medical oncologist, clinical investigator and health outcomes researcher who serves as vice president of research oncology at Flatiron Health. In this role, he leads efforts to leverage Flatiron’s technology platforms and nationwide provider network to gain insights from real-world data that accelerate research and improve quality of care for cancer patients. Prior to joining Flatiron, Neal was professor and chief of the division of hematology and oncology at University Hospitals Cleveland Medical Center and Case Western Reserve University, and associate director for clinical research at the Case Comprehensive Cancer Center. Neal has a national reputation for his research contributions in gastrointestinal malignancies and health services research, including evaluation of new agents, predictors of response and outcome, development of tools to overcome barriers to clinical trial participation, and assessment of the economic impact of care. He currently serves as chair emeritus of the National Cancer Institute Gastrointestinal Cancer Steering Committee, which oversees the development of clinical trials in the publicly-funded clinical trials system. Neal recently completed a four-year term as an elected member of the American Society of Clinical Oncology Board of Directors. He has authored more than 250 manuscripts, book chapters, and editorials related to cancer prevention, treatment, decision making, and health economics. Neal received his undergraduate degree in philosophy from Princeton University and MD from Vanderbilt University. He was a resident in internal medicine at Case Western Reserve University, and completed hematology and medical oncology fellowships at the University of Pennsylvania. He spent a sabbatical at the Leonard Davis Institute of Health Economics at the Wharton School of the University of Pennsylvania.
Follow Neal Meropol:
About Flatiron Health: Flatiron Health is a healthcare technology company that aims to improve lives by learning from the experience of every cancer patient.
Marta Bralic
Senior Vice President of Business Development of Flatiron Health
Marta Bralic Kerns is the Founder & CEO at Pomelo Care. She attended Harvard University.
Follow Marta Bralic:
About Flatiron Health, Pomelo Care: Flatiron Health is a healthcare technology company that aims to improve lives by learning from the experience of every cancer patient.
Thomas Yuen
Chairman, President and CEO of PrimeGen Biotech
Tom Yuen is a proven serial entrepreneur who has founded several successful publicly traded companies including AST Research Inc. and SRS Labs, Inc. (NASDAQ: SRSL). Tom Yuen received his Bachelor of Science degree in Electrical Engineering from the University of California, Irvine in 1974. Tom Yuen Has received many honors including: Director of the Year, Orange County Forum for Corporate Directors (1997), Top 25 Executives, Consumer Industry, Computer Reseller News Magazine (1991 & 1987), The UCI Medal (1990), The UCI Outstanding Engineering Alumni Award (1987), and The UCI Distinguished Alumnus Award (1986).
Follow Thomas Yuen:
About PrimeGen Biotech: PrimeGen Biotech is a privately held stem cell research company dedicated to optimizing the therapeutic potential of adult stem cells.
Tom Yuen
President & CEO of PrimeGen Biotech
Yuen is a proven serial entrepreneur who has founded several successful publicly traded companies including AST Research Inc. and SRS Labs, Inc. (NASDAQ: SRSL). Yuen received his Bachelor of Science degree in Electrical Engineering from the University of California, Irvine in 1974. Yuen Has received many honors including: Director of the Year, Orange County Forum for Corporate Directors (1997), Top 25 Executives, Consumer Industry, Computer Reseller News Magazine (1991 & 1987), The UCI Medal (1990), The UCI Outstanding Engineering Alumni Award (1987), and The UCI Distinguished Alumnus Award (1986).
Follow Tom Yuen:
About PrimeGen Biotech: PrimeGen Biotech is a privately held stem cell research company dedicated to optimizing the therapeutic potential of adult stem cells.
Heather A. Brown
Senior Vice President, Market Access & Reimbursement of HeartFlow
Dr. Brown brings 10 years of experience in advanced medical imaging product development and service. She has held leadership roles in multiple startups and drove the development of AAA stent graft and TAVR planning applications as well as novel methods of assessing cardiac wall mechanics. Dr. Brown developed the first Volumetric Medical Imaging college accredited program at Jefferson Community and Technical College in 2005. She holds six patents. She received her B.S. degree in Mechanical Engineering from Michigan Technological University, and M.S. and Ph.D. degrees in Biomedical Engineering from Vanderbilt University.
Follow Heather A. Brown:
About HeartFlow: HeartFlow is a medical technology company that provides new methods of diagnosis and treatment of cardiovascular disease.
Jason Fisherman
President & CEO of C4 Therapeutics
Follow Jason Fisherman:
About AlloMek Therapeutics, C4 Therapeutics: C4 Therapeutics develops novel early stage therapies that eliminate disease-causing proteins.
Dan L. Dearen
President & Chief Financial Officer of Axonics Modulation Technologies
Follow Dan L. Dearen:
About Axonics Modulation Technologies: Axonics Modulation Technologies is a pre-revenue company developing novel implantable neuromodulation.
Michael McKenna
President & COO of Quantum SI
Michael McKenna is the President and Chief Operating Officer of Quantum-Si since December 2014. Prior to joining Quantum-Si, Dr. McKenna served as Vice President, R&D at Life Technologies Corporation, a global biotechnology company, from August 2011 to July 2014, and as a consultant to Life Technologies from February 2011 to August 2011. Dr. McKenna received his B.S. in molecular biology and German from Carnegie Mellon University and his Ph.D. in biology from Yale University.
Follow Michael McKenna:
About Quantum SI: Quantum SI offers Next Generation Protein Sequencing that makes diagnostics digital.
Adam Bayaa
Vice President of IT & Security of Heal
Adam is Vice President of IT & Security at Heal, and has over 15 years’ experience in the retail, hospitality and healthcare industries.
Follow Adam Bayaa:
About Heal: Heal is an in-home primary care practice that offers modern doctor house calls, one-touch telemedicine and remote monitoring for seniors.
Mike Jensen
Senior Vice President of Operations of Heal
Follow Mike Jensen:
About Heal: Heal is an in-home primary care practice that offers modern doctor house calls, one-touch telemedicine and remote monitoring for seniors.
Srinivasa Nagalla
Founder , President & CEO of DiabetOmics
Dr. Nagalla is the principal founder and chief executive officer of DiabetOmics. He was previously founder and CEO of ProteoGenix, Inc., a successful innovator in maternal-fetal health diagnostics, which was acquired by Hologic, Inc. (HOLX) in 2010. Before founding ProteoGenix, Dr. Nagalla was Associate Professor of pediatrics at Oregon Health & Science University. He is the lead inventor on several key patents on biomarkers for clinical diagnostics, and has previously served on National Institutes of Health-sponsored national consortiums of biotechnology, genomics, and proteomics. Dr. Nagalla has 20+ years of broad multi-disciplinary experience in clinical medicine, biotechnology, and commercialization. Dr. Nagalla received his M.D. from the All-India Institute of Medical Sciences, New Delhi, and post-doctoral training at Harvard University and Oregon Health & Science University.
Follow Srinivasa Nagalla:
About DiabetOmics: DiabetOmics is a medical diagnostics company that provides non-invasive assessment and management of personalized health and diabetes risk.
Charles Roberts
Co-Founder , Vice President and Chief Science Officer of DiabetOmics
Dr. Roberts is co-founder and chief science officer since 2008. Dr. Roberts is a molecular endocrinologist with over 25 years of experience in diabetes research, is an internationally recognized expert on insulin action, and has authored over 250 scientific papers and review articles. Dr. Roberts is also a co-inventor on various patents on therapeutics and biomarkers for clinical diagnostics, and serves on numerous review panels for the National Institutes of Health and the editorial boards of several major biomedical research journals. From 1984-1994, he was a Senior Investigator in the Diabetes Branch of the National Institutes of Health in Bethesda, MD, and subsequently Professor and Associate Chair for Research in the Department of Pediatrics and Professor of Medicine at Oregon Health & Science University.
Follow Charles Roberts:
About DiabetOmics: DiabetOmics is a medical diagnostics company that provides non-invasive assessment and management of personalized health and diabetes risk.
John Buck
Founding Partner & President of Emerus Hospital Partners
Dr. Buck is a founding partner, member of the board of directors and President of Emerus Holdings Inc. With more than 18 years of health care experience as a physician and organizational leader, Buck oversees strategy, regulatory guidance, leadership development and partner relations. Previously, Dr. Buck has held external positions including CEO of Cypress Creek Emergency Center and staff physician with Methodist Health System, Willowbrook. Buck served as an emergency room physician with the U.S. Air Force at Keesler Air Force base in Mississippi and holds a Bachelor of Science from The University of Texas, Dallas, a Medical Degree from The University of Texas Health Science Center, San Antonio and served his residency in emergency medicine at Scott & White, Temple, TX.
Follow John Buck:
About Emerus Hospital Partners: Emerus Hospital is an emergency care facility providing prompt diagnosis, treatments and advanced emergency care services for patients.
C. Geoffrey Davis
President and CSO of Angiocrine Bioscience
C. Geoffrey Davis is the President and CSO of Angiocrine Bioscience, Inc.
Follow C. Geoffrey Davis:
About Angelica Therapeutics, Angiocrine Bioscience, Moerae Matrix: Angiocrine Bioscience develops a cellular platform to amplify stem and progenitor cells in both human and mouse models.
George Winston
Senior Vice President / General Manager Acute Care Division of Sommetrics
33 years in healthcare commerce, including sales, sales management, marketing, marketing management, with Sorenson Research, Abbott Laboratories and Hospira Worldwide and 5i Sciences. This experience spans across several medical device product lines for the hospital critical care, CV surgery, and CV anesthesia markets. The product lines include physiological pressure measurement, continuous mixed venous oxygen saturation monitoring, electronic infusion devices, airway management, sleep apnea and CV Surgery devices. Net result of the assignments is a thorough understanding of the acute care hospital market, with special knowledge of physician and nursing technology needs along with designing and selling products into the anesthesia, critical care and CV surgery areas. Currently V.P. Marketing, 5i Sciences, a medical device start-up with a focus on OSA and airway management in sedated patients, undergoing medical procedures. Experienced in partnership and financial discussions with major potential corporate partners and investors. Areas of experience include: Establishment of a regional critical care sales force with top and bottom line sales accountability, establishment of a KOL referral program, development of sales and product training materials and participation in the product design process, with focus on product usability to enhance clinician acceptability. Education: 1972 – 1975 Florida Atlantic University, Boca Raton, Florida Marketing and business, 1969 – 1971 Miami – Dade College, Miami, Florida A.A.S., Aeronautical Technology. FAA flight certifications include Commercial license, Flight instructor, Instrument flight instructor.
Follow George Winston:
About Adela Health Inc., Keiretsu Forum, Sommetrics, TruPosture: Sommetrics is focused on improving health and well-being by optimizing sleep quality.
Frédéric Sweeney
Vice President, Corporate Development & Strategic Financing Lead of bioMerieux
Dr. Frédéric Sweeney is the vice president, corporate development and strategic financing lead of bioMerieux. Prior to joining bioMerieux, Fred was Vice-President of Business Development & Strategic Alliances for Tornado Spectral Systems (TSS), a commercial stage nanophotonics and spectroscopy technology company strongly driven by an OEM partnership business model. Having joined as an original founding member of the company, Fred managed all aspects of commercialization and go-to-market strategy for TSS’ product portfolio. He led a number of large partnership agreements with world-leading spectroscopy companies and several in/out-licensing deals. Fred also worked as part of the life sciences investment team at VenGrowth Private Equity Partners, one of Canada’s premier private equity and venture capital firms. His main responsibilities at VenGrowth were to provide operational support and coordinate follow-on investments for portfolio companies, as well as sourcing and performing due diligence on new investment opportunities for the firm. Fred also acted as an observer on the Board of numerous companies in the medical device, therapeutic, diagnostic and biomaterials space. Fred holds a Ph.D. in molecular and medical genetics from the University of Toronto as a Terry Fox Scholar of the National Cancer Institute of Canada. During his scientific training, he acquired a deep expertise in clinical diagnostics and cancer biology by using structural and molecular biology as well as small molecule biochemistry.
Follow Frédéric Sweeney:
About bioMerieux: bioMérieux develops and produces in vitro diagnostic solutions for private and hospital laboratories, mainly for the diagnosis.
Jeffrey Nathanson
Vice President, Business Development of 10.10.10
Follow Jeffrey Nathanson:
About 10.10.10: 10.10.10 gives impact entrepreneurs the context and tools to develop market-based solutions.
Alan Rigby
Co-Founder, President & Chief Executive Officer of HiberCell
Alan Rigby is a passionate and innovative oncology leader with over 20 years of academic and industry experience in the area of data driven oncology drug discovery from concept to clinical candidate to genetically enabled first-in-man studies. Dr. Rigby is committed to leveraging patient material and data for use in the identification, stratification and development of ‘next generation’ cancer therapeutics for use in responder populations. This ‘commitment’ has resulted in clinically validated large and small molecule therapeutics for several cancer indications. Most recently, Alan led a prioritized and focused effort to translate ‘Natures Intracellular Biologic’ into transformative medicines for oncology and antibiotic resistance while chief scientific officer of Warp Drive Bio., a Cambridge based biotechnology company that was recently acquired. Alan joined Warp Drive Bio following a tenure as senior vice president and chief scientific officer at Synta Pharmaceuticals. While at Synta Alan led research and development efforts for Synta’s HSP90 clinical candidate, Ganetespib, as well as restructuring the preclinical small molecule drug conjugate platform. Prior to joining Synta, Dr. Rigby was vice president, global antibody drug conjugate biology, and head of external innovation for oncology research at the New York site for Eli Lilly and Company. Before launching his biotech/ pharmaceutical career Dr. Rigby was a National Institutes of Health (NIH) funded assistant professor and principal investigator at Beth Israel Deaconess Medical Center, Harvard Medical School. While at Harvard Medical School, he founded and directed the Drug Discovery and Target Validation Program within the Beth Israel Deaconess Medical Center. As a mentor and advisor Alan continues to work with numerous organizations to assemble and chair scientific conferences with a focus on translating innovative science and oncology-centric platforms into robust and durable clinically validated strategies. Alan Rigby is on the Editorial Advisory Board for Future Medicinal Chemistry, was North American Editor for Current Computer Aided Drug Discovery and has published more than 55 scientific papers, a book chapter and has 12 patents that have published or are pending. Alan holds an Honors BSc. in Biochemistry from the University of Western Ontario in London, Ontario, Canada and a Ph.D. in Biochemistry from the same University.
Follow Alan Rigby:
About HiberCell: HiberCell is a biotechnology company developing treatments to prevent cancer relapse and metastasis.
Joseph Talamo
Senior Vice President and Chief Financial Officer of HiberCell
Joseph Talamo is the Senior Vice President and Chief Financial Officer at HiberCell.
Follow Joseph Talamo:
About HiberCell: HiberCell is a biotechnology company developing treatments to prevent cancer relapse and metastasis.
Satnam Alag
Senior Vice President Software Engineering and Chief Security Officer of Grail
Dr. Alag is a software professional with over fifteen years of commercial software development and management experience, with over twenty years of experience in machine learning and search areas. His expertise is in Big Data technologies, building large-scale multi-tenant SaaS applications, applying intelligence and personalization to Web 2.0 applications, SOA and J2EE architectures, delivering high-quality software, and building high performing engineering teams. He is currently the CTO and VP of Engineering at NextBio. NextBio is a data-driven engine, which is at the intersection of Big Data and genomics. At NextBio, he leads a team that mines billions and billions of data points using the Hadoop stack and commodity hardware. Prior to joining NextBio, he worked as a consultant with Johnson and Johnson’s BabyCenter where he helped develop their personalization engine. Prior to that, he was the Chief Software Architect and Dir. of Application Engineering at Rearden Commerce. He began his career at GE R&D and has held senior technical and management positions at Computing Technologies International and Black Pearl. Satnam is a Sun Certified Enterprise Architect (SCEA) for the Java platform. His doctoral dissertation from the University of California, Berkeley was in the area of probabilistic reasoning and machine learning. He has a number of peer-reviewed publications, holds five patents. He is the author of the book “Collective Intelligence in Action”.
Follow Satnam Alag:
About Grail, Zenufa Laboratories: Grail develops a pan-cancer screening test designed to detect cancers at an early stage.
Malcolm Benitz
President of Medicom Technologies
Follow Malcolm Benitz:
About Medicom Technologies: Medicom is a SaaS Healthcare IT company.
Don Crawford
President and CEO of CorVista Health
Don Crawford, President & Chief Executive Officer, is a seasoned medical device executive with a proven track record of excellent results driven leadership through team efforts and focused execution. Don previously founded and led Sapheon Inc., a cardiovascular-focused medical device company, from inception to $238 million acquisition by Covidien in 2014. His career started with Medtronic and included sales and marketing positions of increasing responsibility with Guidant Corporation, Ventritex, and Intermedics, including an international sales director role in charge of a $100 million cardiovascular business. Don received his B.Ch.E. in Chemical Engineering from Georgia Tech and M.B.A. from Emory University.
Follow Don Crawford:
About CorVista Health: CorVista Health uses artificial intelligence to develop a completely new form of medical imaging for coronary artery disease.
Lynn Crowe
Senior Vice President, Member Advocacy of Livongo
With over 20 years as a healthcare professional focused in diabetes, Lynn has successfully led programs to reduce barriers to proper care for people with diabetes. Starting her career with the American Diabetes Association, Lynn developed programs that were adopted as national prototypes, some of which are still in place today. Upon obtaining her Masters degree in counseling, Lynn joined Sanofi’s diabetes division where she honed her insights into the person with diabetes. She led programs with proven success addressing the psychological challenges of the diseases. Lynn has been recognized as an innovator in the diabetes space receiving numerous awards. In 2011, she co-authored and published “The Diabetes Manifesto: Take Control of Your Life”, a book that has been well received by the community. Upon joining Livongo in 2013, she has helped build Livongo’s client experience and now primarily focuses on member advocacy, ensuring the “Member First” philosophy is incorporated in all we do. Lynn holds a Bachelor of Science in Business and Master of Science in Counseling from the University of Scranton.
Follow Lynn Crowe:
About Livongo: Livongo provides a data science and technology enabled platform for detection of diabetes.
Frank Shields
Vice President of US Sales of Ivantis
Frank Shields currently works as Vice President of US Sales at Ivantis.
Follow Frank Shields:
About Ivantis: Ivantis is focused on developing an innovative treatment for glaucoma which includes eye drops, laser therapy, and surgery.
Richard Hope
Vice President of Clinical and Medical Affairs of Ivantis
Richard Hope currently works as Vice President of Clinical & Medical Affairs at Ivantis.
Follow Richard Hope:
About Ivantis: Ivantis is focused on developing an innovative treatment for glaucoma which includes eye drops, laser therapy, and surgery.
Ken Galt
Vice President of Research and Development of Ivantis
Ken Galt currently works as Vice President of Research and Development at Ivantis.
Follow Ken Galt:
About Ivantis: Ivantis is focused on developing an innovative treatment for glaucoma which includes eye drops, laser therapy, and surgery.
Paul Epner
Executive Vice President of Xip
Follow Paul Epner:
About Society to Improve Diagnosis in Medicine, Xip: Xip produces disposable blood analyzers that wirelessly upload lab-quality clinical measurements in minutes.
Charles Daitch
Founder , CEO & President of Akonni Biosystems
Dr. Daitch is the Founder of Akonni and has served as the CEO and Board member since its inception in 2003. He has 26 years of product development experience in integrated biosensors encompassing a broad range of disciplines including chemistry, biology, biomaterials, engineering, and chemical/biological defense. He manages and leads multidisciplinary teams of scientists and engineers focused on the development of next-generation in-vitro diagnostic devices. Dr. Daitch has experience in developing a wide variety of sensor system products for remote autonomous or point-of-use detection of complex samples employing miniaturized analyte purification, and specialty biomaterials interfaced with microfabricated detection components coupled to a variety signal transduction modalities. He brings strong product development and R&D experience from the NIH/FDA, USDA, Sandia National Labs and the Intelligence Community. In addition, he has commercial senior management experience (P&L responsibility) from PSR/Veridian, CUBRC, HandyLab, and Akonni. Dr. Daitch was recruited by HandyLab Inc., a microfluidics diagnostic company, to serve on the executive management team as Vice President of R&D. Prior, Dr. Daitch launched a biodefense product development facility and business unit for PSR/Veridian Corp., a premier DOD/IC contractor, and led the growth of the operation to 24 employees and >$5M in annual revenue. As the CEO of Akonni he is responsible for 1) setting and executing strategic direction, 2) product management, 3) leading equity financing rounds (>$30M to date), managing capital, financial audits, 4) corporate governance, shareholder relations, 5) leading business development, strategic partnerships, 6) recruiting, mentoring, listening and learning from our exceptional staff, and 7) setting the company’s culture. He has 5 U.S. patents, 24 publications and served as principle investigator on over $20 million in government grants and contracts.
Follow Charles Daitch:
About Akonni Biosystems: Akonni Biosystems is a biotechnology company that develops and manufactures, genetic testing devices.
Robert Glenning
President Financial and Information Technology Services and CFO of Hackensack Meridian Health
Follow Robert Glenning:
About Hackensack Meridian Health: Hackensack Meridian Health is poised to better meet the needs of their communities.
Joseph Lemaire
President of Hackensack Meridian Health
Follow Joseph Lemaire:
About Hackensack Meridian Health: Hackensack Meridian Health is poised to better meet the needs of their communities.
Mark Rothera
President and Chief Executive Officer of Orchard Therapeutics
Mark brings 28 years of experience in the bio-pharmaceutical industry including driving the transition of multiple emerging biotechnology companies from R&D stage to commercialisation. During his career, he has focused on bringing novel therapies to market for patients with rare diseases, and has launched seven orphan drugs. Prior to Orchard Therapeutics, Mark served as Chief Commercial Officer of PTC Therapeutics (“PTC”) where he helped transition the company from a privately funded, US-based R&D biotech to a public, commercial stage company with a 47 country commercialisation footprint. This he achieved by building a global commercialisation capability and successfully launching two rare disease therapies. Prior to joining PTC, Mark served as Global President of Aegerion Pharmaceuticals Inc. and Head EMEA region at Shire Human Genetics. Mark received an M.A. in Natural Sciences from Cambridge University and an MBA from INSEAD.
Follow Mark Rothera:
About Orchard Therapeutics, Silence Therapeutics: Orchard Therapeutics is a biotechnology company dedicated to transforming the lives of patients through innovative gene therapies.
John Cerio
Senior Vice President and Global Head of Human Resources of Orchard Therapeutics
John brings over 25 years of HR leadership experience in the pharmaceutical and biotech industry building high growth, high performance, mission driven and entrepreneurial companies. Until recently John served as Vice President of Human Resources and Administration for Agenus where he led the HR function through periods of rapid growth, transformation and global expansion including the acquisition and integration of 4-antibody AG and the recruiting and on-boarding of over 150 R&D staff, responsible for creating and advancing an Immuno-oncology portfolio of over a dozen clinical candidates including 4 that are currently in phase 2. Prior to Agenus, he was Vice President of Global HR for PerkinElmer Life Sciences during which time the company more than doubled in size and annual sales. Earlier in his career, John spent nearly 10 years with Bristol-Myers Squibb company in a series of HR leadership roles with increasing responsibilities ranging from Director of HR for Corporate Staff to Head of HR for their Oncology and Immunology division. John earned his B.S. in Industrial and Labor Relations from Cornell and his M.A. in Organizational Psychology from Columbia. He also completed the Global Leadership Development Programme at the London Business School.
Follow John Cerio:
About Orchard Therapeutics: Orchard Therapeutics is a biotechnology company dedicated to transforming the lives of patients through innovative gene therapies.
Frank Thomas
President & Chief Operating Officer of Orchard Therapeutics
Frank brings nearly 20 years of experience in the biopharmaceutical industry as an accomplished financial and business executive. Frank has a background developing and executing capital markets strategies for private and public companies as well as experience in operations management, and corporate and business development. Until recently Frank served as president and chief operating officer of AMAG Pharmaceuticals where he helped develop the business from a single product company in 2011 to one with a portfolio of commercial and development-stage products that generated more than $600 million in sales in 2017. During that time, Frank raised more than $1.8 billion in new capital to support the significant growth of AMAG. Before joining AMAG, he served as chief operating officer and chief financial officer for Molecular Biometrics, Inc. Earlier in his career, Frank also served as chief financial officer for Critical Therapeutics and Esperion Therapeutics. Each completed its initial public offering in the United States during his tenure. Frank currently serves on the board of directors of Zafgen (Nasdaq: ZFGN) and Spero Therapeutics (Nasdaq: SPRO). Frank received a Bachelor of Business Administration (BBA) from the University of Michigan, Ann Arbor.
Follow Frank Thomas:
About Orchard Therapeutics: Orchard Therapeutics is a biotechnology company dedicated to transforming the lives of patients through innovative gene therapies.
Daniel Simon
Senior Vice President, BioPharma Business Development of Guardant Health
Follow Daniel Simon:
About Guardant Health: Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs in oncology.
Daniel Grosu
Founder, Chief Executive Officer & President of PetDx
Dr. Daniel Grosu is the Founder and Managing Partner of GenoPraxis, LLC – a San Diego based specialty consultancy dedicated to enabling the practical implementation of genomic testing technologies. He is also an active angel investor, and sits on the Life Science committee of Tech Coast Angels (San Diego). Dr. Grosu previously served as Sequenom’s last Chief Medical Officer (until the company’s acquisition by LabCorp) and as Illumina’s first Chief Medical Officer. He established the Clinical Development and Medical Affairs functions at Illumina, and led the team that performed the clinical studies supporting the FDA clearance and CE Marking of the MiSeqDx platform and associated cystic fibrosis assay – the world’s first NGS-based in-vitro diagnostic (IVD) product. Earlier in his career, Dr. Grosu held positions of increasing responsibility in medical affairs and clinical development at Siemens Medical Solutions, Bayer HealthCare Pharmaceuticals, and Johnson & Johnson. Dr. Grosu holds an MD (with Distinction in Research) from Saint Louis University School of Medicine, Missouri, and an MBA from the University of Oxford, UK.
Follow Daniel Grosu:
About PetDx: PetDx is a molecular diagnostics company dedicated to the detection and treatment of cancer in pets.
Raul Krauss
Co-Founder & Vice President of Disarm Therapeutics
Follow Raul Krauss:
About Disarm Therapeutics: Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Raul Krauss
Co-Founder & Vice President of Disarm Therapeutics
Follow Raul Krauss:
About Disarm Therapeutics: Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Graham Lidgard
Senior Vice President R&D and Chief Science Officer of Exact Sciences
Follow Graham Lidgard:
About Exact Sciences: Exact Sciences is the developer and manufacturer of Cologuard, a non-invasive screening test for the early detection of colorectal cancer.
Adam Logal
Sr. Vice President & Chief Financial Officer of OPKO Health
Mr. Logal has served as OPKO’s Sr. Vice President and Chief Financial Officer since April 2014 and as OPKO’s Vice President of Finance, Chief Accounting Officer and Treasurer since March 2007. From 2002 to 2007, Mr. Logal served in senior management of Nabi Biopharmaceuticals, a publicly traded, biopharmaceutical company engaged in the development and commercialization of proprietary products. Mr. Logal held various positions of increasing responsibility at Nabi Biopharmaceuticals, last serving as Senior Director of Accounting and Reporting. Mr. Logal currently serves on the board of directors of SciVac Therapeutics, Inc. (TSX: VAC), a commercial-stage biopharmaceutical company.
Follow Adam Logal:
About OPKO Health: Opko Health engages in the discovery and development of novel and proprietary technologies for pharmaceuticals and diagnostics.
Steven Rubin
Executive Vice President of OPKO Health
Mr. Rubin has served as Executive Vice President – Administration since May 2007 and as a director of the Company since February 2007. Mr. Rubin served as the Senior Vice President, General Counsel and Secretary of IVAX from August 2001 until September 2006. Mr. Rubin currently serves on the board of directors of SciVac Therapeutics, Inc. (TSX: VAC), a commercial-stage biopharmaceutical company, Tiger Media, Inc. (NYSE MKT:IDI), a multi-platform media company, Kidville, Inc. (OTCBB:KVIL), which operates large, upscale facilities, catering to newborns through five-year-old children and their families and offers a wide range of developmental classes for newborns to five-year-olds, Non-Invasive Monitoring Systems, Inc. (OTCBB:NIMU), a medical device company, Tiger X Medical, Inc. (OTCBB:CDOM), previously an early-stage orthopedic medical device company specializing in designing, developing and marketing reconstructive joint devices and spinal surgical devices, Cocrystal Pharma, Inc. (OTCBB: COCP), formerly Biozone Pharmaceuticals, Inc., a publicly traded biotechnology company developing new treatments for viral diseases, Sevion Therapeutics, Inc. (OTCBB:SVON), a clinical stage company which discovers and develops next-generation biologics for the treatment of cancer and immunological diseases, Castle Brands, Inc. (NYSE MKT:ROX), a developer and marketer of premium brand spirits, and Neovasc, Inc. (TSXV:NVC), a company developing and marketing medical specialty vascular devices. Mr. Rubin previously served as a director of Dreams, Inc. (NYSE MKT: DRJ), a vertically integrated sports licensing and products company, Safestitch Medical, Inc. prior to its merger with TransEnterix, Inc., and PROLOR Biotech, Inc., prior to its acquisition by the Company in August 2013.
Follow Steven Rubin:
About OPKO Health: Opko Health engages in the discovery and development of novel and proprietary technologies for pharmaceuticals and diagnostics.
Tim Kanter
Vice President Market Access, Trade and Pricing of Orphazyme
Tim Kanter is the CCO of Prescient Medicine, a company focused on producing tools that target patient outcomes and management in two key areas – medication interaction and medication efficacy –including the validated genetic test designed to predict individual risk of opioid addiction, LifeKit® Predict. Tim has worked for major pharmaceutical and biopharmaceutical companies including Baxalta/Baxter, Novo Nordisk, and ALTANA Pharma in both US and global roles. Most recently, he consulted with a variety of companies in the preparation and launch of new products and initiatives within multiple therapeutic areas. Tim holds a BS from the University of Florida and an MBA from the University of South Florida.
Follow Tim Kanter:
About Orphazyme: Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disorders called lysosomal storage diseases.
Anjen Chenn
Senior Vice President of Metamark Genetics
Follow Anjen Chenn:
About Metamark Genetics, University of Illinois at Chicago: Metamark Genetics develops prognostic and predictive diagnostic tests that enable personalized treatment planning for cancer patients.
John Mcmannis
Executive Vice President, Manufacturing of Mesoblast
Follow John Mcmannis:
About Mesoblast: Mesoblast is a medicine company that develops biologic products for the broad field of regenerative medicine.
Daniel Cher
Vice President, Clinical Affairs of SI-BONE
Daniel Cher is a board-certified internist with over 15 years of clinical affairs and research experience in a variety of medical device technology companies. His experience includes developing clinical and regulatory strategy, designing and leading clinical trials, directing clinical research, and consulting with a variety of medical device technology companies. Most recently, he served as VP of Clinical and Regulatory Affairs at Chestnut Medical, an early-stage company developing new minimally invasive therapies for Interventional Neuroradiology. At Chestnut, he lead clinical trials and regulatory affairs for the Pipeline Embolization Device, a novel device for the treatment of large and giant intracranial aneurysms, which received FDA approval in April 2011. Prior to this, Dr. Cher served as VP of Clinical and Regulatory Affairs at Pulmonx, Inc., and was Medical Director and VP of Clinical Research at Kyphon, Inc., where he directed clinical research. Educated at Stanford and Yale Universities, Daniel pursued his residency in internal medicine at University of Wisconsin, Madison, and California Pacific Medical Center, in San Francisco. Daniel underwent additional training in general internal medicine and research methods at Stanford University and the Palo Alto VA Hospital. Daniel left clinical practice in 1999 to lead clinical trials at several San Francisco Bay Area medical device technology companies, including Kyphon. Daniel’s focus is on clinical trial design and statistical analysis.
Follow Daniel Cher:
About PROCEPT BioRobotics, SI-BONE, Wild Iris Consulting: SI-BONE advances the diagnostic understanding of lower back pain and minimally invasive surgery for the sacroiliac joint.
Jeffrey Dunn
President and CEO of SI-BONE
Jeffrey Dunn has over thirty years of executive experience, including serving as the CEO of six companies. His medical device experience includes sacroiliac surgery, ankle replacement, and small bone extremity fusion. Jeffrey Dunn has taken one company public, sold all the others to larger public companies, served on numerous boards of directors and is an advisor to other CEOs. Prior to SI-BONE, Inc. Jeffrey Dunn was CEO of INBONE Technologies, which he built into a leading ankle replacement and small bone fusion medical device company. Jeffrey Dunn led the sale of INBONE to Wright Medical in April, 2008. Jeffrey Dunn was the CEO of Active Decisions. Brought in to effect a turnaround, he closed down a major product line and redirected the technology to the “software as a service” model. Active Decisions was bought by Knova Software, a public company that was subsequently sold to Consona, a private equity firm. Previously, Jeffrey Dunn was the CEO of Velogic, an Internet performance testing software company. At Velogic, Jeffrey Dunn reinvented and expanded the product line, restructured the management team and created industry partnerships, one of which ultimately led to the acquisition of the company by Keynote Systems. Jeffrey Dunn was also the CEO of EnterpriseLink, a provider of enterprise Internet enablement software. Jeffrey Dunn was recruited to lead a turnaround by the investors. Jeffrey Dunn reinvigorated the company and successfully sold the company for a substantial gain in less than one year. Jeffrey Dunn was also the CEO of AccelGraphics, a 3D graphics systems supplier. Jeffrey Dunn created AccelGraphics by orchestrating a spin out from Kubota Graphics. He built the company into a rapidly growing enterprise (the 8th fastest growing Silicon Valley public company in 1997). The company was subsequently sold to Evans and Sutherland. Jeffrey Dunn has also held executive positions with Evans and Sutherland, Cygnet Systems, Avnet and Xerox. Jeffrey Dunn holds a BA degree from Colgate University and earned an MBA from Babson College.
Follow Jeffrey Dunn:
About SI-BONE: SI-BONE advances the diagnostic understanding of lower back pain and minimally invasive surgery for the sacroiliac joint.
Scott Yerby
Vice President, Chief Technology Officer of SI-BONE
Scott Yerby has served in an R&D position for several start-up medical device companies for the past 10 years. Most notably, he served as the VP of R&D for St. Francis Medical Technologies, until its acquisition by Kyphon in 2007. Scott has co-authored over 40 peer reviewed publications, 70 abstracts, and 60 patent applications, and been issued 17 patents for a variety of medical technology companies. Prior to entering the medical device technology industry, Dr. Yerby served as the Director of Experimental Biomechanics at the Palo Alto VA Hospital for three years. He has also held appointments as Consulting Assistant Professor at Stanford University in the Department of Mechanical Engineering, Division of Biomechanical Engineering, as well the Department of Functional Restoration, Division of Orthopedic Surgery. Dr. Yerby holds B.S. and M.S. degrees in Mechanical Engineering, and a Ph.D. in Biomedical Engineering, all from University of California, Davis.
Follow Scott Yerby:
About SI-BONE: SI-BONE advances the diagnostic understanding of lower back pain and minimally invasive surgery for the sacroiliac joint.
John Mulcahy
Vice President, Research of SiteOne Therapeutics
John Mulcahy PhD, is a Co-Founder and Vice President of Research at SiteOne. As a postdoctoral fellow and graduate student at Stanford, he developed methods for preparing a family of rare, naturally occurring sodium ion channel pore blockers from simple starting materials. He received his A.B. degree from Harvard University, with concentrations in Chemistry, Physics, and the Classics. Honors include a Stanford Dean’s Postdoctoral Fellowship, a National Science Foundation Predoctoral Fellowship, a Pfizer Summer Research Fellowship and a National Merit Scholarship. Dr. Mulcahy is also a Principal Investigator on multiple small business grants awarded to SiteOne by The National Institutes of Health.
Follow John Mulcahy:
About SiteOne Therapeutics, StartX (Stanford-StartX Fund): SiteOne Therapeutics is a San Francisco-based company that develops novel therapeutics and diagnostics.
Shalabh Gupta
Founder, President & CEO of Globavir
Follow Shalabh Gupta:
About Globavir, Unicycive Therapeutics: A New Approach to Treating Global Infectious Diseases
